These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9616826)

  • 1. [Efficacy and tolerability of pristinamycin vs amoxicillin-clavulanic acid combination in the treatment of acute community-acquired pneumonia in hospitalized adults].
    Poirier R; Chardon H; Beraud A; Debieuvre D; Petitprez P; Montestruc F; Lilienthal F; Janus C
    Rev Pneumol Clin; 1997; 53(6):325-31. PubMed ID: 9616826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
    File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of amoxicillin-clavulanic acid 1000/125mg twice daily extended release (XR) tablet for the treatment of bacterial community-acquired pneumonia in adults.
    Prabhudesai PP; Jain S; Keshvani A; Kulkarni KP
    J Indian Med Assoc; 2011 Feb; 109(2):124-7. PubMed ID: 21888181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults].
    Trémolières F; Mayaud C; Mouton Y; Weber P; Dellatolas F; Caulin E
    Pathol Biol (Paris); 2005; 53(8-9):503-10. PubMed ID: 16181747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
    Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
    J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
    Lode H; Magyar P; Muir JF; Loos U; Kleutgens K;
    Clin Microbiol Infect; 2004 Jun; 10(6):512-20. PubMed ID: 15191378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
    Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
    Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral clindamycin 300 mg BID compared with oral amoxicillin/clavulanic acid 1 g BID in the outpatient treatment of acute recurrent pharyngotonsillitis caused by group a beta-hemolytic streptococci: an international, multicenter, randomized, investigator-blinded, prospective trial in patients between the ages of 12 and 60 years.
    Mahakit P; Vicente JG; Butt DI; Angeli G; Bansal S; Zambrano D
    Clin Ther; 2006 Jan; 28(1):99-109. PubMed ID: 16490583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
    Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
    Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
    Ortiz-Ruiz G; Caballero-Lopez J; Friedland IR; Woods GL; Carides A;
    Clin Infect Dis; 2002 Apr; 34(8):1076-83. PubMed ID: 11914996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prospective and comparative study between cefuroxime, ceftriaxone and amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia].
    Sánchez ME; Gómez J; Gómez Vargas J; Baños V; Ruiz Gómez J; Muñoz L; Simarro E; Soto MC; Canteras M; Valdés M
    Rev Esp Quimioter; 1998 Jun; 11(2):132-8. PubMed ID: 9795298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pristinamycin versus oxacillin in the treatment of superficial pyoderma. A multicenter randomized study in 293 outpatients].
    Bernard P; Vaillant L; Martin C; Beylot C; Quentin R; Touron D
    Ann Dermatol Venereol; 1997; 124(5):384-9. PubMed ID: 9739895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.
    Oh HM; Ng AW; Lee SK
    Singapore Med J; 1996 Jun; 37(3):255-7. PubMed ID: 8942221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections.
    Granizo JJ; Aguilar L; Gimenez MJ; Coronel P; Gimeno M; Prieto J
    Rev Esp Quimioter; 2009 Jun; 22(2):57-61. PubMed ID: 19544097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections.
    Balgos AA; Rodriguez-Gomez G; Nasnas R; Mahasur AA; Margono BP; Tinoco-Favila JC; Sansores-Martinez RH; Hassan M; Beppo O; Wongsa A; Cukier A; Vargas F
    Int J Clin Pract; 1999; 53(5):325-30. PubMed ID: 10695094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.